Inhibition of map4k4 through rnai
AssigneeRXi Pharmaceuticals Corporation
InventorsTod M Woolf, Joanne Kamens, Anastasia Khvorova, William Salomon
Life of this patent
Estimating the term…
Loading patent…
AssigneeRXi Pharmaceuticals Corporation
InventorsTod M Woolf, Joanne Kamens, Anastasia Khvorova, William Salomon
Estimating the term…
RNAi constructs directed to MAP4K4 that demonstrate unexpectedly high gene silencing activities, and uses thereof are disclosed. The blunt-ended constructs have a double-stranded region of 19-49 nucleotides. The constructs have selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the strands may be modified (e.g., one or both ends of the sense strand is modified by 2′-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, the antisense strand may also be modified by a 2′-O-methyl group at the penultimate 5′-end nucleotide to greatly reduce off-target silencing.
An RNAi construct for inhibiting expression of a MAP4K4 gene, comprising an antisense sequence that has complementarity to a target sequence on an mRNA of the MAP4K4 gene, wherein the target sequence comprises at least 12 contiguous nucleotides of SEQ ID NO:
3-5. (canceled)
(canceled)
11-20. (canceled)
22-24. (canceled)
26-34. (canceled)
36-37. (canceled)
39-61. (canceled)
(canceled)
65-71. (canceled)
(canceled)
Dependencies are inferred from the claim text.